Cancer nanomedicine toward clinical translation: Obstacles, opportunities, and future prospects
- Authors
- Zhang, Pengfei; Xiao, Yufen; Sun, Xue; Lin, Xiaoning; Koo, Seyoung; Yaremenko, Alexey V.; Qin, Duotian; Kong, Na; Farokhzad, Omid C.; Tao, Wei
- Issue Date
- Mar-2023
- Publisher
- Cell Press
- Keywords
- cancer nanomedicine; clinical translation; current status; future prospects
- Citation
- Med, v.4, no.3, pp 147 - 167
- Pages
- 21
- Indexed
- SCOPUS
ESCI
- Journal Title
- Med
- Volume
- 4
- Number
- 3
- Start Page
- 147
- End Page
- 167
- URI
- https://scholarworks.bwise.kr/erica/handle/2021.sw.erica/118938
- DOI
- 10.1016/j.medj.2022.12.001
- ISSN
- 2666-6359
2666-6340
- Abstract
- With the integration of nanotechnology into the medical field at large, great strides have been made in the development of nanomedicines for tackling different diseases, including cancers. To date, various cancer nanomedicines have demonstrated success in preclinical studies, improving therapeutic outcomes, prolonging survival, and/or decreasing side effects. However, the translation from bench to bedside remains challenging. While a number of nanomedicines have entered clinical trials, only a few have been approved for clinical applications. In this review, we highlight the most recent progress in cancer nanomedicine, discuss current clinical advances and challenges for the translation of cancer nanomedicines, and provide our viewpoints on accelerating clinical translation. We expect this review to benefit the future development of cancer nanotherapeutics specifically from the clinical perspective. © 2022 Elsevier Inc.
- Files in This Item
-
- Appears in
Collections - COLLEGE OF SCIENCE AND CONVERGENCE TECHNOLOGY > DEPARTMENT OF CHEMICAL AND MOLECULAR ENGINEERING > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.